突触囊泡糖蛋白2A中的双变异与性脑病变有关
Almundher Al-Maawali1,2, Fathiya Al-Murshedi1, Amna Al-Futaisi3
1Department of Genetics, Sultan Qaboos University Hospital, Sultan Qaboos University, Muscat, Oman.
突触囊糖蛋白2A (SV2A) 基因变异导致早期发病的耐药性. 在SV2A中功能丧失突变导致儿童出现严重的神经症状,突出其关键作用.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 是一个遗传学.
- 的研究研究.
背景情况:
- 突触膀糖蛋白2A (SV2A) 是一个关键的突触膀蛋白,也是 levetiracetam 的目标.
- 之前的研究发现,一家人患有与SV2A突变 (Arg383Gln) 相关的难治性.
研究的目的:
- 在第二个家庭中调查早期发病的抗药性的遗传基础.
- 识别与严重现型相关的SV2A基因中的新型变异.
主要方法:
- 在受影响的个人和家庭成员身上进行了整体外基因组测序.
- 进行分离分析以确认鉴定变异的遗传模式.
- 与现有文献和小鼠模型进行了表型相关性.
主要成果:
- 在受影响的儿童中,发现了SV2A基因中的同卵性Arg289Ter变异.
- 这种变异在家族内与现型分离.
- 受影响的儿童从婴儿期开始出现反复发作的发作,发育迟缓和发育不良,与之前的发现和SV2A淘汰赛小鼠模型相一致.
结论:
- 在SV2A中双性功能丧失变体是人类早期发作的难治的原因.
- 这些发现强调了SV2A在正常神经发育和功能中的关键作用.
- 对SV2A功能的进一步研究可能会揭示的新治疗标.
更多相关视频
09:07Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins
Published on: August 15, 2017
08:22A Novel Strategy Combining Array-CGH, Whole-exome Sequencing and In Utero Electroporation in Rodents to Identify Causative Genes for Brain Malformations
Published on: December 1, 2017
相关概念视频
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Antiepileptic Drugs: Glutamate Antagonists
Lysosomal Hydrolases
Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
Arteries of the Lower Limbs
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
